We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

41 hedge funds and large institutions have $235M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

37% more capital invested

Capital invested by funds: $172M → $235M (+$63.1M)

8% more funds holding

Funds holding: 38 → 41 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
41
Holders Change
+3
Holders Change %
+7.89%
% of All Funds
0.64%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
5
Increased
10
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$20.7M
2
EHI
Eagle Health Investments
Connecticut
+$2.94M
3
GTC
Ghost Tree Capital
New York
+$271K
4
SFM
Sphera Funds Management
Israel
+$198K
5
UOC
UBS O'Connor
Illinois
+$141K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$2.49M
2
AG
Artal Group
Luxembourg
-$1.08M
3
Millennium Management
Millennium Management
New York
-$299K
4
Two Sigma Investments
Two Sigma Investments
New York
-$59.1K
5
VF
Virtu Financial
New York
-$49K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$49.8M +$20.7M +4,784,689 +82%
APM
2
Avidity Partners Management
Texas
$26.6M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$21.9M – – –
JJ
4
Johnson & Johnson
New Jersey
$17.1M – – –
Canada Pension Plan Investment Board
5
Canada Pension Plan Investment Board
Ontario, Canada
$14.6M – – –
O
6
OrbiMed
New York
$14.6M – – –
ASP
7
Adams Street Partners
Illinois
$13.8M – – –
DM
8
Deerfield Management
New York
$13.2M – – –
PA
9
Perceptive Advisors
New York
$12.8M -$36.9K -8,541 -0.3%
TGA
10
TPG GP A
Texas
$11.9M – – –
AG
11
Artal Group
Luxembourg
$8.06M -$1.08M -250,000 -13%
PBPIA
12
Pivotal bioVenture Partners Investment Advisor
California
$7.29M – – –
SFM
13
Sphera Funds Management
Israel
$6.21M +$198K +45,721 +4%
1832 Asset Management
14
1832 Asset Management
Ontario, Canada
$3.43M – – –
EHI
15
Eagle Health Investments
Connecticut
$3.18M +$2.94M +680,370 New
GTC
16
Ghost Tree Capital
New York
$1.93M +$271K +62,699 +18%
Millennium Management
17
Millennium Management
New York
$1.56M -$299K -69,211 -17%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$1.54M – – –
UOC
19
UBS O'Connor
Illinois
$1.28M +$141K +32,542 +13%
SCM
20
Sio Capital Management
New York
$1.15M – – –
Morgan Stanley
21
Morgan Stanley
New York
$643K +$83.8K +19,376 +16%
SI
22
Sofinnova Investments
California
$547K – – –
UBS Group
23
UBS Group
Switzerland
$439K +$18K +4,174 +5%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$305K +$128K +29,500 +82%
SAM
25
Sectoral Asset Management
Quebec, Canada
$268K – – –
1
2

FUSN Hedge Fund Activity: Q2 2023 in Review

41 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2023, worth a combined $235M — up 37% from $172M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new FUSN positions and 2 closed out — a net gain of 3 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was Federated Hermes, adding an estimated $20.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.49M sold.

  • 41 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2023, up from 38 in Q1 2023.
  • Funds reported $235M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2023, up 37% quarter-over-quarter.
  • 5 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2023 and 2 closed out, a net change of +3 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2023 was Federated Hermes, an estimated $20.7M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2023 was RA Capital Management, an estimated $2.49M sold.

Based on aggregated 13F filings for Q2 2023.